← Back to Screener
PMV Pharmaceuticals, Inc (PMVP)
Price$1.12
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-23.08%
Price vs S&P 500 (4W)-20.56%
VGM Score47.82
Market Capitalization$59.73M
All Metrics
Book Value / Share (Quarterly)$1.65
P/TBV (Annual)0.47x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.41
Price vs S&P 500 (YTD)-18.56%
EPS (TTM)$-1.48
10-Day Avg Trading Volume0.32M
EPS Excl Extra (TTM)$-1.48
EPS (Annual)$-1.48
ROI (Annual)-74.24%
Cash / Share (Quarterly)$1.75
ROA (Last FY)-66.70%
EBITD / Share (TTM)$-1.58
ROE (5Y Avg)-37.34%
Cash Flow / Share (Annual)$-1.38
P/B Ratio0.68x
P/B Ratio (Quarterly)0.75x
Net Income / Employee (Annual)$-1,439,700
ROA (TTM)-62.70%
EPS Incl Extra (Annual)$-1.48
Current Ratio (Annual)10.09x
Quick Ratio (Quarterly)10.88x
3-Month Avg Trading Volume0.56M
52-Week Price Return17.89%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.64
52-Week High$1.88
EPS Excl Extra (Annual)$-1.48
CapEx CAGR (5Y)-28.01%
26-Week Price Return-15.15%
Quick Ratio (Annual)9.89x
13-Week Price Return-26.80%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.14x
Enterprise Value$20.60M
Book Value / Share Growth (5Y)-24.52%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.12
3-Month Return Std Dev52.19%
Net Income / Employee (TTM)$-1,450,800
ROE (Last FY)-74.24%
EPS Basic Excl Extra (Annual)$-1.48
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.48
ROI (TTM)-68.98%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.38
Price vs S&P 500 (52W)-6.47%
Year-to-Date Return-10.40%
5-Day Price Return-8.94%
EPS Normalized (Annual)$-1.48
ROA (5Y Avg)-33.86%
Month-to-Date Return-6.67%
Cash Flow / Share (TTM)$-1.54
EBITD / Share (Annual)$-1.64
ROI (5Y Avg)-37.34%
EPS Basic Excl Extra (TTM)$-1.48
P/TBV (Quarterly)0.48x
P/B Ratio (Annual)0.64x
Book Value / Share (Annual)$1.96
Price vs S&P 500 (13W)-35.05%
Beta1.35x
Revenue / Share (TTM)$0.00
ROE (TTM)-68.98%
52-Week Low$0.91
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.34est. -0.42
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.25
4.25
4.18
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PMVPPMV Pharmaceuticals, Inc | — | — | C | $1.12 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
PMV Pharmaceuticals is a precision oncology company developing small molecule therapies targeting p53 mutations to treat cancer across multiple tumor types. Its lead program, rezatapopt, is being evaluated in combination with azacitidine, with additional candidates including PC14586 and PMV-586-101 in its pipeline.